Loading
Life sciences · Journal article
Medcomm · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Liquid biopsy has evolved over two decades from an extension of tissue genotyping into a minimally invasive approach for repeat and longitudinal molecular assessment across the cancer continuum. Advances in sequencing, digital PCR, error suppression, and computational analytics have expanded analytes beyond circulating tumor DNA and circulating tumor cells to extracellular vesicles, circulating RNAs, and tumor‐educated platelets, while broadening readouts from mutations to methylation, fragmentomics, transcriptomics, proteomics, and multiomic integration. This review traces the field from its technological foundations to current applications in early detection and multicancer early detection, therapy selection and resistance monitoring, minimal residual disease, recurrence‐risk stratification, and longitudinal response assessment across major cancers and selected nononcologic settings. We distinguish clinically established applications from emerging and exploratory strategies and emphasize that high analytical performance does not by itself establish clinical utility. We further discuss preanalytical handling, standardization, biological confounders, and evidence required for implementation. Future progress will depend on use‐case‐driven development, prospective utility studies, longitudinal and multimodal interpretation, and integration with established diagnostic pathways. Together, these priorities define a transition from molecular detectability toward reproducible, actionable, and clinically meaningful liquid biopsy.